Cargando…

Perspective on mTOR-dependent Protection in Status Epilepticus

Background: The piriform cortex, known as area tempestas, has a high propensity to trigger limbic epileptic seizures. Recent studies on human patients indicate that a resection containing the piriform cortex produces a marked improvement in patients suffering from intractable limbic seizures. This c...

Descripción completa

Detalles Bibliográficos
Autores principales: Biagioni, Francesca, Celli, Roberta, Giorgi, Filippo Sean, Nicoletti, Ferdinando, Fornai, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886823/
https://www.ncbi.nlm.nih.gov/pubmed/34636300
http://dx.doi.org/10.2174/1570159X19666211005152618
_version_ 1784880202628726784
author Biagioni, Francesca
Celli, Roberta
Giorgi, Filippo Sean
Nicoletti, Ferdinando
Fornai, Francesco
author_facet Biagioni, Francesca
Celli, Roberta
Giorgi, Filippo Sean
Nicoletti, Ferdinando
Fornai, Francesco
author_sort Biagioni, Francesca
collection PubMed
description Background: The piriform cortex, known as area tempestas, has a high propensity to trigger limbic epileptic seizures. Recent studies on human patients indicate that a resection containing the piriform cortex produces a marked improvement in patients suffering from intractable limbic seizures. This calls for looking back at the pharmacological and anatomical data on area tempestas. Within the piriform cortex, status epilepticus can be induced by impairing the desensitization of AMPA receptors. The mechanistic target of rapamycin complex1 (mTORC1) is a promising candidate. Objective: The present perspective aims to link the novel role of the piriform cortex with recent evidence on the modulation of AMPA receptors under the influence of mTORC1. This is based on recent evidence and preliminary data, leading to the formulation of interaction between mTORC1 and AMPA receptors to mitigate the onset of long-lasting, self-sustaining, neurotoxic status epilepticus. Methods: The perspective grounds its method on recent literature along with the actual experimental procedure to elicit status epilepticus from the piriform cortex and the method to administer the mTORC1 inhibitor rapamycin to mitigate seizure expression and brain damage. Results: The available and present perspectives converge to show that rapamycin may disrupt the seizure circuitry initiated in the piriform cortex to mitigate seizure duration, severity, and brain damage. Conclusion: The perspective provides a novel scenario to understand refractory epilepsy and self- sustaining status epilepticus. It is expected to provide a beneficial outcome in patients suffering from temporal lobe epilepsy.
format Online
Article
Text
id pubmed-9886823
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-98868232023-02-09 Perspective on mTOR-dependent Protection in Status Epilepticus Biagioni, Francesca Celli, Roberta Giorgi, Filippo Sean Nicoletti, Ferdinando Fornai, Francesco Curr Neuropharmacol Neurology Background: The piriform cortex, known as area tempestas, has a high propensity to trigger limbic epileptic seizures. Recent studies on human patients indicate that a resection containing the piriform cortex produces a marked improvement in patients suffering from intractable limbic seizures. This calls for looking back at the pharmacological and anatomical data on area tempestas. Within the piriform cortex, status epilepticus can be induced by impairing the desensitization of AMPA receptors. The mechanistic target of rapamycin complex1 (mTORC1) is a promising candidate. Objective: The present perspective aims to link the novel role of the piriform cortex with recent evidence on the modulation of AMPA receptors under the influence of mTORC1. This is based on recent evidence and preliminary data, leading to the formulation of interaction between mTORC1 and AMPA receptors to mitigate the onset of long-lasting, self-sustaining, neurotoxic status epilepticus. Methods: The perspective grounds its method on recent literature along with the actual experimental procedure to elicit status epilepticus from the piriform cortex and the method to administer the mTORC1 inhibitor rapamycin to mitigate seizure expression and brain damage. Results: The available and present perspectives converge to show that rapamycin may disrupt the seizure circuitry initiated in the piriform cortex to mitigate seizure duration, severity, and brain damage. Conclusion: The perspective provides a novel scenario to understand refractory epilepsy and self- sustaining status epilepticus. It is expected to provide a beneficial outcome in patients suffering from temporal lobe epilepsy. Bentham Science Publishers 2022-05-16 2022-05-16 /pmc/articles/PMC9886823/ /pubmed/34636300 http://dx.doi.org/10.2174/1570159X19666211005152618 Text en © 2022 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Neurology
Biagioni, Francesca
Celli, Roberta
Giorgi, Filippo Sean
Nicoletti, Ferdinando
Fornai, Francesco
Perspective on mTOR-dependent Protection in Status Epilepticus
title Perspective on mTOR-dependent Protection in Status Epilepticus
title_full Perspective on mTOR-dependent Protection in Status Epilepticus
title_fullStr Perspective on mTOR-dependent Protection in Status Epilepticus
title_full_unstemmed Perspective on mTOR-dependent Protection in Status Epilepticus
title_short Perspective on mTOR-dependent Protection in Status Epilepticus
title_sort perspective on mtor-dependent protection in status epilepticus
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886823/
https://www.ncbi.nlm.nih.gov/pubmed/34636300
http://dx.doi.org/10.2174/1570159X19666211005152618
work_keys_str_mv AT biagionifrancesca perspectiveonmtordependentprotectioninstatusepilepticus
AT celliroberta perspectiveonmtordependentprotectioninstatusepilepticus
AT giorgifilipposean perspectiveonmtordependentprotectioninstatusepilepticus
AT nicolettiferdinando perspectiveonmtordependentprotectioninstatusepilepticus
AT fornaifrancesco perspectiveonmtordependentprotectioninstatusepilepticus